Masmoudi Doryan, Villalba Martin, Alix-Panabières Catherine
Laboratory of Rare Circulating Human Cells, University Medical Center of Montpellier, Montpellier, France.
IRMB, Univ Montpellier, INSERM, CHU Montpellier, CNRS, Montpellier, France.
J Exp Clin Cancer Res. 2025 Apr 10;44(1):118. doi: 10.1186/s13046-025-03375-x.
Natural killer (NK) play a key role in controlling tumor dissemination by mediating cytotoxicity towards cancer cells without the need of education. These cells are pivotal in eliminating circulating tumor cells (CTCs) from the bloodstream, thus limiting cancer spread and metastasis. However, aggressive CTCs can evade NK cell surveillance, facilitating tumor growth at distant sites. In this review, we first discuss the biology of NK cells, focusing on their functions within the tumor microenvironment (TME), the lymphatic system, and circulation. We then examine the immune evasion mechanisms employed by cancer cells to inhibit NK cell activity, including the upregulation of inhibitory receptors. Finally, we explore the clinical implications of monitoring circulating biomarkers, such as NK cells and CTCs, for therapeutic decision-making and emphasize the need to enhance NK cell-based therapies by overcoming immune escape mechanisms.
自然杀伤(NK)细胞在介导对癌细胞的细胞毒性以控制肿瘤播散方面发挥着关键作用,且无需经过预刺激。这些细胞对于从血液中清除循环肿瘤细胞(CTC)至关重要,从而限制癌症的扩散和转移。然而,侵袭性CTC能够逃避NK细胞的监视,促进肿瘤在远处部位生长。在本综述中,我们首先讨论NK细胞的生物学特性,重点关注它们在肿瘤微环境(TME)、淋巴系统和循环中的功能。然后,我们研究癌细胞用来抑制NK细胞活性的免疫逃逸机制,包括抑制性受体的上调。最后,我们探讨监测循环生物标志物(如NK细胞和CTC)对治疗决策的临床意义,并强调通过克服免疫逃逸机制来加强基于NK细胞的治疗的必要性。